key: cord-0756797-m3d0r3mf
authors: Castellanos-Gonzalez, Alejandro; Shelite, Thomas R.; Lloyd, Nicole; Sadiqova, Aygul; Ping, Ren; Williams-Bouyer, Natalie; Melby, Peter C.; Travi, Bruno L.
title: Direct RT-PCR amplification of SARS-CoV-2 from clinical samples using a concentrated viral lysis-amplification buffer prepared with IGEPAL-630
date: 2021-07-09
journal: Sci Rep
DOI: 10.1038/s41598-021-93333-2
sha: 36dc37f0103237d6c3295ad2eae8f86acfb0e6ca
doc_id: 756797
cord_uid: m3d0r3mf

The pandemic of 2019 caused by the novel coronavirus (SARS-CoV-2) is still rapidly spreading worldwide. Nucleic acid amplification serves as the gold standard method for confirmation of COVID-19 infection. However, challenges faced for diagnostic laboratories from undeveloped countries includes shortage of kits and supplies to purify viral RNA. Therefore, it is urgent to validate alternative nucleic acid isolation methods for SARS-CoV-2. Our results demonstrate that a concentrated viral lysis amplification buffer (vLAB) prepared with the nonionic detergent IGEPAL enables qualitative detection of SARS-CoV-2 by direct Reverse Transcriptase-Polymerase Chain Reaction (dRT-PCR). Furthermore, vLAB was effective in inactivating SARS-CoV-2. Since this method is inexpensive and no RNA purification equipment or additional cDNA synthesis is required, this dRT-PCR with vLAB should be considered as an alternative method for qualitative detection of SARS-CoV-2.

All methods were carried out in accordance with guidelines and regulations in methods section. 

diluted in vLAB to evaluate virus inactivation. Before the infection, 10 μL of mNG-SARS-CoV-2 (1 × 10 7 PFU/ mL) were diluted with 90 μL of vLAB. Some samples were incubated at room temperature (RT) for 10 min, and other samples were incubated at RT for 20 min. Post-incubation, 10 μL from each sample or MEM media (negative control) were added to each well of a Falcon 12-well plate seeded with 5 × 10 4 cells/well in 2 mL Gibco 1X MEM with 10% fetal bovine serum and gentamycin. Each condition (negative control, positive control, 10 min, and 20 min) was run in triplicate. Plates were incubated at 37 °C with 5% CO 2 for 3 days and then analyzed by fluorescent microscopy. To confirm inactivation, from the first passage plate, 10 μL of supernatant was inoculated in triplicate onto another 12-well plate seeded with 5 × 10 4 cells/well in 2 mL of 10% 1X MEM. This plate was incubated again at 37 °C for 3 days and then analyzed by microscopy as before. Inactivation experiments were conducted in BSL-3 facilities (Dr. Bukreyev's laboratory at UTMB) and the inactivation protocol was approved by the Institutional Biosafety Committee at UTMB dPCR from pure SARS-Cov-2 RNA and inactivated cells.

For these experiments, we used SARS-Cov-2 RNA (ranging from 0-50,000 copies) obtained from WRCEVA or supernatants of infected cells previously inactivated with vLAB as described above. We conducted all RT-PCR amplifications with the Quantabio RT-qPCR Tough Mix Kit and we used primers and probes for nucleocapsid (N1 and N2) designed by CDC included in the 2019-nCov CDC EUA Kit, 1000 rxn (Integrated DNA Technologies, Coralville, Iowa). After adding template (2 µL) to RT-PCR master mix, reaction (20 µL total volume) was transferred to PCR 96 well plates (Applied Biosystems, Foster City CA) and amplification was conducted in a 7500 Fast Real-Time PCR System (Applied Biosystem) using the following conditions: 50 °C for 15 min, 95 °C for 5 min, then 45 cycles of 95° C 3 s and 55 °C for 45 s. All clinical samples and controls were tested in triplicate.

dRT-PCR and RT-PCR from clinical samples. We evaluated dRT-PCR amplification in vLAB and for some experiments we compared dRT-PCR vs standard RT-PCR for SARS-CoV-2. For direct amplification, we used RT-PCR conditions, reagents and clinical samples diluted as described before. For standard amplification we purified SARS-CoV-2 RNA using QIAamp Viral RNA Mini Kit (Qiagen, Valencia CA) following vendor protocol provided by WRCEVA. For clinical samples, we used 100µL in VTM treated with Trizol followed by modified chloroform separation and RNA isolation using the Qiagen RNeasy Mini Kit (Qiagen). The cDNA synthesis was carried out using the iScript Select cDNA Synthesis Kit (Bio-Rad) following the manufacturer's protocol or the purified RNA was stored at − 80 °C until use. All clinical samples were previously analyzed in the clinical diagnostic laboratory at UTMB. For SARS-CoV-2 detection, the laboratory used the Panther Fusion System. The Fusion SARS-CoV-2 assay involves the following steps: sample lysis, nucleic acid capture, elution transfer, and multiplex RT-PCR. Nucleic acid capture and elution takes place in a single tube on the Panther Fusion system. The eluate is transferred to the Panther Fusion system reaction tube containing the assay reagents. Multiplex RT-PCR is then performed for the eluted nucleic acid on the Panther Fusion system. The Panther Fusion SARS-CoV-2 assay amplifies and detects two conserved regions of the ORF1ab gene in the same fluorescence channel, 

IGEPAL-630 has been previously used for direct RT-PCR amplification and RNA sequencing 9,10 . Our goal here was to use this reagent to conduct direct amplification in suspected COVID-19 samples. However, is not known if IGEPAL-630 affects SARS-CoV-2 RNA integrity or if this detergent inhibits activity of enzymes included in the RT-PCR COVID detection kits approved by CDC. To adress this question, initially we tested amplification of viral RNA spiked in a viral Lysis Amplification Buffer (vLAB) [0.25% IGEPAL, 150 mM NaCL, Tris 10 mM, BSA 1X] using FDA aproved primers/probes for detection of nucleocapside genes N1 and N2. For these experiments, we used serial dilutions (tenfold) of pure RNA diluted in vLAB or water following CDC protocol. We evaluated RT-PCR performance comparing standard curves of RNA in water vs vLAB. Coefficients of correlation (R 2 ) obtained from standard curves showed identical values for N1 and N2 genes in both samples ( Fig. 1 ) and CT values with minimal variation (Supplementary Fig. 1) showing the same limit of detection of 5 copies per reaction, and slope and E value (E = PCR efficiency) also did not show significant differences between samples diluted in vLAB and water. These results demonstrated that vLAB buffer does not affect SARS-Cov2 RNA integrity and does not inhibit PCR reagents during amplification.

Clinical samples collected in COVID-19 patients are commonly manipulated in BSL-2 laboratories for diagnostic purposes. Therefore, to avoid the risk of exposure of laboratory workers SARS-CoV-2 must first be inactivated 14 . Other groups have demonstrated that detergents like sodiumdodecyl-sulfate (SDS) and Triton-X100 added to guanidinium thiocyanate-lysis buffers can reduce virus infectivity. However, inactivation of SARS-CoV-2 with IGEPAL-630 has not previously been determined. Thus, here we investigated the effect of vLAB on virus replication using a fluorescent SARS-CoV-2 strain (stable mNeonGreen) to infect Vero E6 cells. For these experiments, virus was diluted in MEM culture medium (positive control) or vLAB and then samples were incubated 10 and 20 min. After incubation, the samples were used to infect cultured cells (Pass 1).

We analyzed infection on monolayers of Vero E6 cells by fluorescent microscopy after 3 days of inoculation. Microscopy analysis showed no infection in groups of cells exposed to virus incubated with vLAB for 10 and 20 min; only fluorescence in the positive control was observed ( Fig. 2A) . To confirm viral inactivation, supernatants obtained from pass 1 were used to re-infect Vero E6 cells (Pass 2). However, only untreated samples (positive control) showed viral replication and no infection was detected in samples treated with vLAB (Fig. 2B) . Overall, Figure 1 . PCR efficiency of SARS-CoV-2 RNA in vLAB. PCR efficiency (E) for N1 and N2 gene was assessed using a duplicate tenfold dilution series of SARS-CoV-2 viral RNA. Linear regression was performed to obtain the slope and R2. The percentage efficiency was calculated from the slope using the formula E = 100 × (− 1 + 10 − 1/slope). vLAB virus Lysis Amplification Buffer. www.nature.com/scientificreports/ 

Our initial results demonstrated feasibility to amplify pure RNA diluted in vLAB. However, clinical samples can contain inhibitory molecules that can affect PCR. Therefore, we tested if SARS-CoV-2 from cell lysates can be amplified directly by standard RT-PCR (CDC protocol). For these experiments, we diluted 10 µL of Vero E6 cells infected with SARS-CoV-2 (1 × 10 7 pfu/mL) with 90 µl of vLAB (Pass 1, P1 sample). We incubated the sample for 10 or 20 min at room temperature and then we tested direct amplification using as template 2 µL of P1. In addition, we tested lysates from P2 ( Table 1) . As expected, we only had amplification in samples from P1 but not in negative samples (uninfected) , which demonstrated the feasibility of direct amplification (Table 1 ). In P1 samples, we observed CT values of 31-33 in samples incubated for 10 min and over time the CT values increased by 2 cycles (36-35 for 20 min). These results suggest that samples stored at room temperature are susceptible to degradation over the time. This degradation could be explained due to residual activity of RNAses. Therefore, physical or chemical inactivation of RNAses must be conducted in clinical samples inactivated with vLAB.

Heated RNA of SARS-Cov-2 is amplified by dRT-PCR. We investigated the effect of temperature on dRT-PCR using samples of viral RNA diluted in vLAB as template. For these experiments, we incubated RNA spiked in vLAB at 65 °C for 10 min and 95 °C for 2 min. The results showed a slight variation in PCR efficiency in the samples incubated at room temperature (Fig. 3) . However, overall, the limit of detection (5 copies per reaction) and CT values were not affected by high temperature and similar values to amplification at room temperature were observed. This result confirmed that vLAB and high temperature does not affect RNA integrity or downstream PCR amplification. Thus, it should be feasible to use heat for enzymatic inactivation on infected cells diluted in vLAB.

We investigated the effect of temperature on dRT-PCR using infected cells in vLAB as template. We hypothesized that heat inactivation of RNAses reduces viral RNA degradation in samples inactivated with vLAB, therefore, incubation of samples in vLAB at high temperature should enhance PCR amplification. To test this hypothesis, we investigated the effect of high temperature on direct amplification using lysates of infected cells in vLAB as template. Samples heated at 65 °C × 10 min and 95 °C × 2 min showed similar CT values. However, these CT values are lower (Table 2) compared with values previously obtained in samples incubated at room temperature. Thus, amplification is more efficient in heated samples. This result confirms that incubation of samples obtained in vLAB at high temperatures enhance amplification of SARS-CoV-2 by RT-PCR. Therefore, enzymatic heat inactivation should be an included step to enhance sensitivity of the assay in clinical samples inactivated with vLAB.

Since the goal of this preliminary work was to demonstrate the feasibility to conduct direct amplification of COVID-19 samples, we next tested direct amplification in heat-inactivated clinical samples that were diluted in vLAB. We used 30 nasopharyngeal clinical In other experiments, we conducted a blinded study to evaluate the performance of dRT-PCR in clinical samples (previously tested at UTMB clinical laboratory) with high and low viral loads (Table 4 ). In these experiments, the dRT-PCR in vLAB method detected 100% of the positive and negative samples with high loads (< 30 CT) and only 1 positive sample with low viral load was not detected since the CT value was out of the limit of detection (CT 40). This result demonstrates the feasibility to use concentrated vLAB for direct amplification of SARS-CoV-2 in heat-inactivated samples. Importantly, we realize that validation of this method with a larger number of clinical samples is needed.

We showed that a viral lysis amplification buffer (vLAB) prepared with IGEPAL allows dRT-PCR amplification of SARS-CoV-2 using primers and protocols approved by the CDC. The COVID-19 pandemic has resulted in an unprecedented worldwide demand for PCR testing. The huge increase in molecular testing has resulted in shortages of PCR reagents, viral transport media (VTM), and viral RNA extraction kits. This problem is exacerbated mainly in undeveloped countries and remote areas where the supply chain for reagents is inefficient. Our goal in this work was to test inexpensive alternatives for molecular detection of SARS-CoV-2 that could be implemented in these low resource settings. We considered that dRT-PCR amplification could be a low-cost alternative for SARS-CoV-2 detection since this technique does not require RNA extraction kits nor specialized equipment for extraction. Currently, there are several commercial reagents for dRT-PCR, however, we decided to test an inexpensive protocol reported by Shatzkes et al. 10 . This method is based on the use of a lysis amplification buffer prepared with IGEPAL-630 (octylphenoxypolyethoxyethanol). This reagent is a nonionic, non-denaturing detergent that has been used for Table 3 . Direct amplification of clinical samples in vLAB. Clinical samples from positive (Pos) and negative (Neg) patients were purified with QIAGEN RNA extraction kit or diluted with vLAB. The CT values from RT-PCR amplification with RNA extracted with QIAGEN and vLAB.

Lab result CT N1 CT N2 CT N1 CT N2   1  Neg  ND  ND  ND  ND   2  Neg  ND  ND  ND  ND   3  Neg  ND  ND  ND  ND   4  Neg  ND  ND  ND  ND   5  Neg  ND  ND  ND  ND   6  Neg  ND  ND  ND  ND   7  Neg  ND  ND  ND  ND   8  Neg  ND  ND  ND  ND   9 Neg ND ND ND ND www.nature.com/scientificreports/ solubilization, isolation, and purification of membrane protein complexes 9, 10 . Since IGEPAL is a mild detergent that induces cellular lysis but does not inhibit PCR enzymes 9,10 , we hypothesized that vLAB (prepared with IGEPAL) would be optimal for detecting SARS-CoV-2 RNA by dRT-PCR. Our initial studies showed that vLAB components do not inhibit activity of reverse transcriptase and DNA polymerase included in the tested amplification kit since we did not observe differences between RNA spiked in vLAB or water (Fig. 1) . Our initial studies showed that a vLAB component does not affect activity of reverse transcriptase and DNA polymerase included in the amplification kit (Fig. 1) . To date, CDC has approved more than 10 RT-PCR kits for COVID detection (https:// www. fda. gov/ media/ 134922/ downl oad). These kits should also be individually tested for dRT-PCR with vLAB. However, since enzymatic activities and amplification reagents included in all approved kits are similar, we anticipate that there will not be significant differences. RNA preservation after sample collection is essential to maximize sensitivity and specificity of the detection assay. To prevent degradation, we evaluated two heating temperatures with the objective to inhibit RNAase activity. Both tested temperatures did not affect amplification of spiked RNA in the vLAB samples. Recent studies have demonstrated that virus inactivation is achieved at 70 °C and here we confirmed heat inactivation in infected cells which were lysed and diluted in vLAB. In addition, we demonstrated the feasibility of conducting dRT-PCR amplification in these samples. The vLAB inactivation will allow sample handling in BSL-2 laboratories, thereby reducing the exposure risk of personnel. Clinical samples used in this study were collected in VTM (~ 3 ml), to enhance viral concentration in the sample, and we used 9 parts of VTM and 1 part of a concentrated solution (10x) of vLAB. Our initial assessment with clinical samples showed a 100% correlation in dRT-PCR with vLAB and RT-PCR conducted with RNA purified in our laboratory with a commercial kit, however, we observed variation in CT values that may reflect differences in viral load or sample degradation. To address this question, we www.nature.com/scientificreports/ conducted additional experiments to evaluate performance of dRT-PCR in samples with differences in viral load. We found that in samples with high viral load (Low CT values < 30) we obtained 100% correlation, however, the sensitivity was slightly reduced in samples with high CTs. These results suggest that slight variations in CT values may be due to sample degradation during transportation or multiple thawing. A larger experiment with fresh samples should be conducted to validate dRT-PCR results for samples that are close to the limit of detection. Overall, our results verified that using vLAB for molecular diagnostics of SARS-CoV-2 is a feasible method that should be pursued. Since IGEPAL-630 is an inexpensive reagent, the protocol described here could represent an affordable alternative for developing countries or remote areas for molecular detection of SARS-CoV-2.

Raw data supporting the findings of this study are available from the corresponding author upon reasonable request. www.nature.com/scientificreports/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): A global pandemic and treatment strategies

Early diagnosis and rapid isolation: Response to COVID-19 outbreak in Korea

Diagnosing COVID-19: The disease and tools for detection

Laboratory testing methods for novel severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2)

Types of assays for SARS-CoV-2 testing: A review

US CDC real-time reverse transcription PCR panel for detection of severe acute respiratory syndrome coronavirus 2. Emerg

Comparing the analytical performance of three SARS-CoV-2 molecular diagnostic assays

Overcoming the bottleneck to widespread testing: A rapid review of nucleic acid testing approaches for COVID-19 detection

An optimised direct lysis method for gene expression studies on low cell numbers

A simple, inexpensive method for preparing cell lysates suitable for downstream reverse transcription quantitative PCR

Direct DNA amplification from crude clinical samples using a PCR enhancer cocktail and novel mutants of Taq

Direct buffer composition of blood pre-process for nucleic acid based diagnostics

Direct cell lysis for single-cell gene expression profiling

Heat inactivation of the severe acute respiratory syndrome coronavirus 2

This work was supported in part by NIH Rapid Acceleration of Diagnostics (RADx), phase 0 award (5403) and Institute for Human Infections and Immunity (IHII) at UTMB (pilot award).

The authors declare no competing interests.

The online version contains supplementary material available at https:// doi. org/ 10. 1038/ s41598-021-93333-2.Correspondence and requests for materials should be addressed to A.C.-G.Reprints and permissions information is available at www.nature.com/reprints.Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.